- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05430958
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
November 12, 2022 updated by: Inovio Pharmaceuticals
Phase 1 Open Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Intradermal Booster Dose of INO-4800 Alone or in Combination With INO-9112 Followed by Electroporation, in Adults Who Completed a Primary Immunization Series Against SARS-CoV-2 With mRNA Vaccines
This is an open label, phase 1 clinical trial of an intra-dermal booster dose of INO-4800 alone or in combination with INO-9112 followed by electroporation (EP) among healthy adults at least 18 years of age, who previously completed their primary immunization series with mRNA vaccines against SARS-CoV-2 within 6-12 months prior to the booster dose.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy men and non-pregnant women at least 18 years of age;
- Able and willing to comply with all study procedures;
- Screening laboratory results within normal limits or deemed not clinically significant by the Investigator;
- Received full primary series doses of an approved or authorized mRNA vaccine at least 6 months but no more than 12 months prior to INO-4800 booster dose.
Must meet one of the following criteria with respect to reproductive capacity:
- Women who are post-menopausal as defined by reported spontaneous amenorrhea for ≥ 12 months;
- Surgically sterile (i.e., vasectomy in males or tubal ligation, absence of ovaries and/or uterus in females). In the case of vasectomy, participants should wait six (6) months post-vasectomy prior to enrollment;
- Use of medically effective contraception with a failure rate of < 1% per year when used consistently and correctly from screening until Day 28 post booster dose.
Exclusion Criteria:
- Acute febrile illness with temperature >100.4°F (38.0°C) or acute onset of upper or lower respiratory tract symptoms (e.g., cough, shortness of breath, sore throat) within the prior 72 hours;
- Positive SARs-CoV-2 PCR test, if results are available prior to dosing;
- Pregnant or breastfeeding, or intending to become pregnant or intending to father children within the projected duration of the study starting from the Screening visit until Day 28 post booster dose;
- Positive pregnancy test during screening or immediately prior to booster dose;
- Positive HIV rapid test, Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody at Screening;
- Is currently participating or has participated in a study with an IP within 30 days preceding Day 0 (documented receipt of placebo in a previous study would be permissible for study eligibility);
- Currently participating in another study with an investigational product during the conduct of this study;
- Previous or planned receipt of any COVID-19 booster vaccine during the trial period
Medical conditions as follows:
- Respiratory diseases
- History of hypersensitivity or severe allergic reaction
- Uncontrolled hypertension
- Uncontrolled diabetes mellitus
- Malignancy within the past 2 years, with the exception of superficial skin
- History of cardiovascular disease
- History of myocarditis or pericarditis
- History of seizures within the past 2 years
- Underlying immunosuppressive illness
- Lack of acceptable sites for ID injection and EP
- Blood donation or transfusion within 1 month prior to Day 0;
- Reported alcohol or substance abuse/dependence or illicit drug use within the past year;
- Any non-study vaccine (e.g., influenza vaccine) within 2 weeks prior to the dose of IP.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Single injection of 0.8 mg of INO-4800 followed by EP administered at Day 0
|
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
|
Experimental: Group 2
Single injection of 0.8 mg of INO-4800 plus 0.05 mg of INO-9112 followed by EP administered at Day 0
|
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
|
Experimental: Group 3
Single injection of 0.8 mg of INO-4800 plus 0.10 mg of INO-9112 followed by EP administered at Day 0
|
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
|
Experimental: Group 4
Single injection of 0.8 mg of INO-4800 plus 0.20 mg of INO-9112 followed by EP administered at Day 0
|
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
|
Experimental: Group 5
Two injections of 0.8 mg (1.6 mg total) of INO-4800 followed by EP administered at Day 0
|
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
|
Experimental: Group 6
Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.05 mg (0.1 mg total) of INO-9112 followed by EP administered at Day 0
|
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
|
Experimental: Group 7
Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.1 mg (0.20 mg total) of INO-9112 followed by EP administered at Day 0
|
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
|
Experimental: Group 8
Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.20 mg (0.40 mg total) of INO-9112 followed by EP administered at Day 0
|
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants with Solicited Local and Systemic Adverse Events (AEs)
Time Frame: Baseline up to Day 7
|
Baseline up to Day 7
|
Percentage of Participants with Adverse Events (AEs)
Time Frame: Baseline up to Day 28
|
Baseline up to Day 28
|
Percentage of Participants with Serious Adverse Events (SAEs)
Time Frame: Baseline up to week 52
|
Baseline up to week 52
|
Percentage of Participants with Adverse Events of Special Interest (AESIs)
Time Frame: Baseline up to week 52
|
Baseline up to week 52
|
Percentage of Participants with Incidence of medically attended AEs (MAAEs)
Time Frame: Baseline up to week 52
|
Baseline up to week 52
|
Percentage of Participants with Change in SARS-CoV-2 pseudovirus neutralizing titers
Time Frame: Baseline up to day 28
|
Baseline up to day 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with a Change in SARS-CoV-2 pseudovirus neutralizing titers
Time Frame: Baseline, Day 7, 14, 84, 180, 224, 280 and 365 post-booster
|
Baseline, Day 7, 14, 84, 180, 224, 280 and 365 post-booster
|
Number of Participants with SARS-CoV-2 pseudovirus neutralizing titers
Time Frame: Days 7, 14, 28, 84, 180, 224, 280 and 365 post-booster
|
Days 7, 14, 28, 84, 180, 224, 280 and 365 post-booster
|
Number of Participants with ARS-CoV-2 Spike binding IgG and change in SARS-CoV-2 Spike binding IgG
Time Frame: Days 7, 14, 28, 84, 180 and 365 post-booster
|
Days 7, 14, 28, 84, 180 and 365 post-booster
|
Number of Participants with SARS-CoV-2 cellular immune response as measured by IFN-gamma ELISpot
Time Frame: Day 14 post-booster
|
Day 14 post-booster
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jose Suaya, MD, Inovio Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2022
Primary Completion (Anticipated)
March 1, 2024
Study Completion (Anticipated)
March 1, 2024
Study Registration Dates
First Submitted
June 21, 2022
First Submitted That Met QC Criteria
June 21, 2022
First Posted (Actual)
June 24, 2022
Study Record Updates
Last Update Posted (Actual)
November 17, 2022
Last Update Submitted That Met QC Criteria
November 12, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVID19-131
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronavirus Infection
-
The University of Hong KongHospital Authority, Hong KongCompletedNovel Coronavirus InfectionHong Kong
-
Affiliated Hospital to Academy of Military Medical...Beijing 302 HospitalUnknownNovel Coronavirus Infection PneumoniaChina
-
ProgenaBiomeDSCS CRORecruitingCOVID-19 | Coronavirus Infection | COVID | Corona Virus Infection | Coronavirus | Sars-CoV2 | Coronavirus-19 | Coronavirus 19United States
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
Concern GRANITSamara State Medical UniversityCompletedCoronavirus Infection COVID-19Russian Federation
-
D'Or Institute for Research and EducationUnknown
-
Chelsea and Westminster NHS Foundation TrustUnknownCOVID-19 | COVID-19 Infection | 2019 Novel Coronavirus InfectionUnited Kingdom
-
Institut National de la Santé Et de la Recherche...Recruiting
-
Kansas City Heart Rhythm InstituteTerminated
-
Universidade Federal de Sao CarlosTerminatedCoronavirus InfectionBrazil
Clinical Trials on INO-4800
-
Inovio PharmaceuticalsAdvaccine (Suzhou) Biopharmaceuticals Co., Ltd.TerminatedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Infection | COVID-19 DiseaseUnited States, Mexico, Colombia
-
Inovio PharmaceuticalsCoalition for Epidemic Preparedness InnovationsCompletedCoronavirus InfectionUnited States
-
Inovio PharmaceuticalsGeneOne Life Science, Inc.; Defense Advanced Research Projects AgencyCompleted
-
Hoffmann-La RocheCompletedHuman Papilloma Virus (HPV)United States
-
Inovio PharmaceuticalsCompleted
-
Inovio PharmaceuticalsUniversity of PennsylvaniaCompletedAerodigestive Precancerous Lesions and MalignanciesUnited States
-
International Vaccine InstituteInovio Pharmaceuticals; Coalition for Epidemic Preparedness InnovationsCompletedCoronavirus Infection | SARS-CoV 2Korea, Republic of
-
Inovio PharmaceuticalsUniversity of PennsylvaniaCompletedHead and Neck Squamous Cell CancerUnited States
-
Inovio PharmaceuticalsMayo Clinic; University of Pennsylvania; University of Pittsburgh; Thomas Jefferson... and other collaboratorsCompletedBreast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | ColoRectal Cancer | HepatoCellular CarcinomaUnited States
-
Inovio PharmaceuticalsCompletedProstate CancerUnited States